On Remand, Federal Circuit Rules Unfair Competition Claim Preempted By BPCIA

(December 14, 2017, 4:04 PM EST) -- WASHINGTON, D.C. — The Federal Circuit U.S. Court of Appeals on Dec. 14 deemed allegations by a drug maker that a competitor violated California’s unfair competition law (UCL), Calif. Bus. & Prof. Code § 17200 et seq., preempted by the Biologics Price Competition and Innovation Act of 2009 (BPCIA), 42 U.S.C. § 262, 35 U.S.C. § 271(e), 28 U.S.C. § 2201(b), 21 U.S.C. § 355 et seq. (Amgen Inc. v. Sandoz Inc., No. 15-1499, Fed. Cir.)....